CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • THC Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Reddit
  • 8-K Filing

Tenet Healthcare (THC) 8-KTenet Announces Leadership Transition

Filed: 10 Aug 21, 7:00am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Tenet Announces Leadership Transition
    • Download Excel data file
    • View Excel data file
    THC similar filings
    • 8 Nov 21 Tenet and USPI to Acquire SurgCenter Development and Establish Long-Term Development Partnership
    • 20 Oct 21 Results of Operations and Financial Condition
    • 3 Sep 21 Departure of Directors or Certain Officers
    • 10 Aug 21 Tenet Announces Leadership Transition
    • 2 Aug 21 Tenet Completes Sale of Five Hospitals
    • 21 Jul 21 Results of Operations and Financial Condition
    • 21 Jun 21 Other Events
    Filing view
    Share this filing

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report: August 5, 2021

    (Date of earliest event reported)

     

     

    TENET HEALTHCARE CORPORATION

    (Exact name of Registrant as specified in its charter)

     

     

     

    Nevada 1-7293 95-2557091
    (State of Incorporation) 

    (Commission

    File Number)

     

    (IRS Employer

    Identification Number)

    14201 Dallas Parkway

    Dallas, TX 75254

    (Address of principal executive offices, including zip code)

    (469) 893-2200

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, $0.05 par value THC NYSE
    6.875% Senior Notes due 2031 THC31 NYSE

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging Growth Company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On August 9, 2021, Tenet Healthcare Corporation (the “Company”) announced that, in furtherance of the Company’s long-term succession plan, Ronald A. Rittenmeyer will transition from Chief Executive Officer of the Company and continue as the Executive Chairman of the Company and the Board of Directors of the Company through 2022, and Saumya Sutaria, M.D., will be promoted from President and Chief Operating Officer of the Company to the Chief Executive Officer of the Company, in each case effective as of September 1, 2021. Dr. Sutaria will continue to report to Mr. Rittenmeyer. The Board of Directors of the Company approved the transition on August 5, 2021.

    The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K with respect to Dr. Sutaria is included in the Company’s annual proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2021, and is hereby incorporated by reference herein.

     

    Item 7.01

    Regulation FD Disclosure.

    A copy of the press release announcing the matters described above is attached to this report as Exhibit 99.1 and incorporated herein by reference. The information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    99.1  Press Release issued on August 9, 2021
    104  Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    - 2 -


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       TENET HEALTHCARE CORPORATION
        Date: August 10, 2021  By: 

    /s/ Thomas Arnst

      Name: Thomas Arnst
      Title: 

    Executive Vice President, Chief

    Administrative Officer and General Counsel

     

    - 3 -

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn